Login to Your Account

Clinic Roundup

Thursday, June 7, 2012

• Hyperion Therapeutics Inc., of South San Francisco, said a 178-patient Phase II study of glycerol phenylbutyrate, a pre-prodrug of phenylacetic acid, in episodic hepatic encephalopathy (HE) met its primary endpoint.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription